We and others have previously shown that targeting platelet-collagen interactions during cerebral ischemia, namely antibody mediated depletion of platelet GPVI or blockade of platelet binding to the vessel walls by Revacept, a GPVI-Fc fusion protein competitively inhibiting GPVI, reduced microvascular thrombosis and infarct volumes after a transient middle cerebral artery occlusion (tMCAO) in mice [13,14,15]. The gene discussed is GP6; the disease is brain ischemia.